| Trial ID: | L0467 |
| Source ID: | JPRN-UMIN000036560
|
| Associated Drug: |
Canagliflozin
|
| Title: |
The efficacy and safety of Canagliflozin for the treatment of NAFLD/NASH patients with type2 DM - The efficacy and safety of Canagliflozin for the treatment of NAFLD/NASH patients with type2 DM
|
| Acronym: |
--
|
| Status: |
Recruiting
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
NAFLD/NASH
|
| Interventions: |
Patients were treated with Canagliflozin
|
| Outcome Measures: |
The liver function after Canagliflozin administration for 24weeks1. The lipid and glycometabolism after Canagliflozin administration for 24weeks<br>2. The safety of Canagliflozin
|
| Sponsor/Collaborators: |
Nippon Medical School Chiba Hokusoh Hospital
Division of Gastroenterology
|
| Gender: |
All
|
| Age: |
18years-old75years-old
|
| Phases: |
Not applicable
|
| Enrollment: |
30
|
| Study Type: |
Interventional
|
| Study Designs: |
Single arm Non-randomized
|
| Start Date: |
01/05/2019
|
| Completion Date: |
31/03/2022
|
| Results First Posted: |
--
|
| Last Update Posted: |
12 July 2021
|
| Locations: |
Japan
|
| URL: |
https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000041655
|
